Breaking News Bar

Business News and Information

ChemoCentryx Investors With Losses Greater Than $100,000 - Kehoe Law Firm, P.C. Securities Class Action Investigation

Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C.

Class Action Investigation On Behalf Of ChemoCentryx Investors With Significant Losses

PHILADELPHIA, PA, USA, May 6, 2021 /EINPresswire.com/ -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”) (NASDAQ: CCXI) to determine whether the Company engaged in securities fraud or other unlawful business practices.

On May 5, 2021, a class action lawsuit was filed in United States District Court, Northern District of California (3:21-cv-03343), on behalf of ChemoCentryx investors who purchased, or otherwise acquired, the Company’s securities between November 26, 2019 and May 3, 2021, both dates inclusive (the “Class Period”).

According to the class action complaint, throughout the Class Period and in violation of the Exchange Act, the ChemoCentryx Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts to investors. Specifically, the ChemoCentryx Defendants, allegedly, misrepresented and/or failed to disclose to investors that (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s NDA for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, the ChemoCentryx Defendants’ public statements were materially false and misleading at all relevant times.

INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, CHEMOCENTRYX SECURITIES DURING THE CLASS PERIOD AND SUFFERED LOSSES GREATER THAN $100,000 ARE ENCOURAGED TO CONTACT KEVIN CAULEY, DIRECTOR, CLIENT RELATIONS, (215) 792-6676, EXT. 802, KCAULEY@KEHOELAWFIRM.COM, SECURITIES@KEHOELAWFIRM.COM, INFO@KEHOELAWFIRM.COM, TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION OR POTENTIAL LEGAL CLAIMS.

Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.

This press release may constitute attorney advertising.

Kevin Cauley, Director, Client Relations
Kehoe Law Firm, P.C.
+1 215-792-6676
info@kehoelawfirm.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear